Evolution of RAS mutational status in liquid biopsies during first-line chemotherapy for metastatic colorectal cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: In: Frontiers in oncology, 10, Article 1115, S. 1115-1-1115-11

Event: Veröffentlichung

(where): Bochum

(who): Ruhr-Universität Bochum

(when): 2020

Creator: Klein-Scory, Susanne
Wahner, Ingo
Maslova, Marina
Al-Sewaidi, Yosef
Pohl, Michael
Mika, Thomas
Ladigan, Swetlana
Schroers, Roland
Baraniskin, Alexander

URN: urn:nbn:de:hbz:294-75906

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:37 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Klein-Scory, Susanne
Wahner, Ingo
Maslova, Marina
Al-Sewaidi, Yosef
Pohl, Michael
Mika, Thomas
Ladigan, Swetlana
Schroers, Roland
Baraniskin, Alexander
Ruhr-Universität Bochum

Time of origin

2020

Other Objects (12)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Pembrolizumab as first-line treatment for metastatic uveal melanoma

MEK targeting in N-RAS mutated metastatic melanoma

Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

RAS testing in metastatic colorectal cancer: advances in Europe

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Pembrolizumab as first-line treatment for metastatic uveal melanoma

MEK targeting in N-RAS mutated metastatic melanoma

Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

RAS testing in metastatic colorectal cancer: advances in Europe

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Pembrolizumab as first-line treatment for metastatic uveal melanoma

MEK targeting in N-RAS mutated metastatic melanoma

Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

RAS testing in metastatic colorectal cancer: advances in Europe

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Evolution of RAS mutational status in liquid biopsies during first-line chemotherapy for metastatic colorectal cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Pembrolizumab as first-line treatment for metastatic uveal melanoma

MEK targeting in N-RAS mutated metastatic melanoma

Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

RAS testing in metastatic colorectal cancer: advances in Europe

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Pembrolizumab as first-line treatment for metastatic uveal melanoma

MEK targeting in N-RAS mutated metastatic melanoma

Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

RAS testing in metastatic colorectal cancer: advances in Europe

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Pembrolizumab as first-line treatment for metastatic uveal melanoma

MEK targeting in N-RAS mutated metastatic melanoma

Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

RAS testing in metastatic colorectal cancer: advances in Europe

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma

Related objects

Reset password